Adapalene is a stable naphthoic acid derivative that displays a strong retinoid agonist pharmacology. This drug controls cell proliferation and differentiation, and possesses significant anti-inflammatory action. The retinoid action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RARβ and RARγ. We describe here how an aqueous gel containing adapalene was selected for the topical treatment of acne.

Charpentier B, Bernardon JM, Eustache J, Millois C, Martin B, Michel S, Shroot B: Syntheses, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J Med Chem 1995;38: 4993–5006.
Shroot B: Medicinal chemistry in dermatology; in Priestley GC (ed): Molecular Aspects of Dermatology. Chichester, Wiley & Sons, 1993, pp 189–209.
Lehman PA, Slatery JT, Franz TJ: Percutaneous absorption of retinoids: Influence of vehicle, light exposure, and dose. J Invest Dermatol 1988;91:56–61.
Schaefer H, Watts F, Brod J, Illel B: Follicular penetration; in Scott RC, Guy RH, Hadgraft J (eds): Prediction of Percutaneous Penetration: Methods, Measurements, Modeling. London, IBC Technical Services, 1990, pp 163–173.
Bailly J, Delescluse C, Bernardon JM, Charpentier B, Martin B, Pilgrim WR, Shroot B, Darmon M: Differentiation of F9 embryonal carcinoma cells by synthetic retinoids: Amplitude of plasminogen activator production does not depend on retinoid potency or affinity for F9 nuclear retinoic acid receptors. Skin Pharmacol 1990;3:256–267.
Michel S, Courseaux A, Miquel C, Bernardon JM, Schmidt R, Shroot B, Thacher SM, Reichert U: Determination of retinoid activity by an enzyme-linked immunosorbent assay. Anal Biochem 1991;192:232–236.
Lotan R, Kramer RH, Neumann G. Lotan D, Nicholson GL: Retinoic acid induced modifications in the growth and cell surface components of a human carcinoma (HeLa) cell line. Exp Cell Res 1980;130:401–414.
Cavey MT, Martin B, Carlavan I, Shroot B: In vitro binding of retinoids to the nuclear retinoic acid receptor α. Anal Biochem 1993; 186:19–23.
Bouclier M, Chatelus A, Ferracin J, Delain C, Shroot B, Hensby CN: Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique. Skin Pharmacol 1991;4:65–73.
Allec J, Chatelus A, Wagner N: Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol, in press.
Hensby CN, Carey D, Bouclier M, Chatelus A, Algate D, Eustache J, Shroot B: The in vivo and in vitro anti-inflammatory activity of CD271: A new retinoid-like modulator of cell differentiation. Agents Actions 1990;29: 56–58.
Bouclier M, Luginbuhl B, Shroot B, Hensby CN: Arachidonic-acid-induced ear oedema in four strains of rats and mice: A comparative study of anti-inflammatory drugs. Agents Actions 1990;29:62–64.
Jamoulle JC, Grandjean L, Lamaud E, Shroot B, Schaefer H: Follicular penetration and distribution of topically applied CD271, a new naphthoic acid derivative intended for topical acne treatment. J Invest Dermatol 1990;94: 731.
Chambon P: The retinoid signal pathway: Molecular and genetic analyses. Cell Biol 1994;5: 115–125.
Griffiths CEM, Elder JT, Bernard BA, Rossio P, Cromie MA, Finkel LJ, Shroot B, Voorhees JJ: Comparison of CD271 (adapalene) and all trans-retinoic acid in human skin: Dissociation of epidermal effects and CRABP-II mRNA expression. J Invest Dermatol 1992; 101:325–328.
Elder JT, Aström A, Pettersson U, Tavakkol A, Griffiths CEM, Krust A, Kastner P, Chambon P, Voorhees JJ: Differential regulation of retinoic acid receptors and binding proteins in human skin. J Invest Dermatol 1992;98: 673–679.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.